title: Regression of human prostate tumors and metastases in nude mice following treatment with the recombinant oncolytic vaccinia virus GLV-1h68.
abstract: Virotherapy using oncolytic vaccinia virus strains is one of the most promising new strategies for cancer therapy. In the current study, we analyzed the therapeutic efficacy of the oncolytic vaccinia virus GLV-1h68 against two human prostate cancer cell lines DU-145 and PC-3 in cell culture and in tumor xenograft models. By viral proliferation assays and cell survival tests, we demonstrated that GLV-1h68 was able to infect, replicate in, and lyse these prostate cancer cells in culture. In DU-145 and PC-3 tumor xenograft models, a single intravenous injection with GLV-1h68 resulted in a significant reduction of primary tumor size. In addition, the GLV-1h68-infection led to strong inflammatory and oncolytic effects resulting in drastic reduction of regional lymph nodes with PC-3 metastases. Our data documented that the GLV-1h68 virus has a great potential for treatment of human prostate carcinoma.
authors.affiliation: Genelux Corporation, San Diego Science Center, San Diego, CA 92109, USA.
authors.forename: Ivaylo
authors.initials: I
authors.lastname: Gentschev
authors.forename: Ulrike
authors.initials: U
authors.lastname: Donat
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Hofmann
authors.forename: Stephanie
authors.initials: S
authors.lastname: Weibel
authors.forename: Marion
authors.initials: M
authors.lastname: Adelfinger
authors.forename: Viktoria
authors.initials: V
authors.lastname: Raab
authors.forename: Martin
authors.initials: M
authors.lastname: Heisig
authors.forename: Nanhai
authors.initials: N
authors.lastname: Chen
authors.forename: Yong A
authors.initials: YA
authors.lastname: Yu
authors.forename: Jochen
authors.initials: J
authors.lastname: Stritzker
authors.forename: Aladar A
authors.initials: AA
authors.lastname: Szalay
mesh_terms: D000818:Animals; D000951:Antigens, Neoplasm / Q000378:metabolism; D016923:Cell Death; D045744:Cell Line, Tumor; D000949:Histocompatibility Antigens Class II / Q000276:immunology; D006801:Humans; D008207:Lymphatic Metastasis / Q000473:pathology; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology; D008297:Male; D051379:Mice; D008819:Mice, Nude; D009363:Neoplasm Proteins / Q000378:metabolism; D050130:Oncolytic Virotherapy / Q000379:methods*; D050504:Oncolytic Viruses / Q000502:physiology*; D011471:Prostatic Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy* / Q000821:virology*; D011995:Recombination, Genetic / Q000235:genetics*; D012074:Remission Induction; D014616:Vaccinia virus / Q000502:physiology*; D014779:Virus Replication / Q000502:physiology; D023041:Xenograft Model Antitumor Assays
chemical_list: D000951:Antigens, Neoplasm; D000949:Histocompatibility Antigens Class II; D009363:Neoplasm Proteins